We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS Withdraws Checkpoint Inhibitor Opdivo for Liver Cancer Indication
BMS Withdraws Checkpoint Inhibitor Opdivo for Liver Cancer Indication
Bristol Myers Squibb (BMS) is withdrawing from the U.S. market the indication for its immune checkpoint inhibitor Opdivo (nivolumab) as a single agent for patients with hepatocellular carcinoma (HCC) who were previously treated with sorafenib.